Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04801615
  4. Details
NCT04801615 Clinical Trial

Characteristics of Patients With Necrotizing Soft Tissue Infections

Necrotizing Soft Tissue Infection Clinical Trial

Official title:
Demographic Characteristics, Symptoms, Treatment and Mortality of Patients With Necrotizing Soft Tissue Infections

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04801615
Other study ID # ICD_20201212
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date June 1, 2025

Study information
Verified date August 2023
Source Aarhus University Hospital
Contact per gundtoft
Phone 26195112
Email pergun@rm.dk
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

To study the demographic characteristic of patients with necrotizing soft tissue infections.

Description:

At Aarhus University Hospital, Denmark, all patients with necrotizing soft tissue infections will be registered in a database in order to be able to describe their symptoms, demographic variables and thier treatment (surgery, time to surgery, antibiotics, intensive care unit, laboratory data etc).

Recruitment information / eligibility
Status Recruiting
Enrollment 30
Est. completion date June 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients diagnosed with necrotizing soft tissue infections and treated at Aarhus Universital Hospital

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Surgery
All patients in the database undergo surgery due to a suspicion of necrotizing soft tissue infections

Locations
Country Name City State
Denmark Aarhus University Hospital Aarhus N

Sponsors (1)
Lead Sponsor Collaborator
Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Percentage of patients that dies within 1 year following admission date The risk of death within 1 year 12 months following admission date
See also
  Status Clinical Trial Phase
Terminated NCT05157360 - HAT for the Treatment of Sepsis Associated With NASTI Phase 1/Phase 2
Withdrawn NCT02314468 - Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation N/A
Recruiting NCT05116956 - SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Terminated NCT03403751 - Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury Phase 3
Terminated NCT05032625 - To Evaluate the Outcomes After Surgery for Necrotizing Soft Tissue Infections
Recruiting NCT05243966 - Myriad™ Augmented Soft Tissue Reconstruction Registry
Active, not recruiting NCT06126263 - Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections
Completed NCT02501382 - Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Completed NCT03147352 - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Completed NCT02180906 - Biomarkers in Patients With Flesh-eating Bacterial Infections N/A
Recruiting NCT06002607 - Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections
Completed NCT02111161 - Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Phase 2
Recruiting NCT03482245 - The Role of Circadian Clock Proteins in Innate and Adaptive Immunity N/A